Journal of Cancer Research and Clinical Oncology最新文献

{"title":"Targeted therapies in primary vaginal cancer.","authors":"Laura Tascón Padrón, Carolin Schröder, Milka Marinova, Thore Thiesler, Luzia A Otten, Glen Kristiansen, Alexander Mustea, Eva K Egger","doi":"10.1007/s00432-025-06267-x","DOIUrl":"10.1007/s00432-025-06267-x","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 8","pages":"228"},"PeriodicalIF":2.8,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12336100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of TACE alone versus TACE combined with synchronous ablation for neuroendocrine neoplasms with liver metastases.","authors":"Sun Huiyi, Wang Feihang, Yav Sothea, Zhao Danyang, Huo Zihao, Shuai Junqi, Yan Zhiping, Chen Yi, Liu Liang, Wang Wenquan, Ji Yuan, Liu Lingxiao","doi":"10.1007/s00432-025-06274-y","DOIUrl":"10.1007/s00432-025-06274-y","url":null,"abstract":"<p><strong>Objective: </strong>To compare the efficacy and safety between thermal ablation combined with synchronous TACE and TACE in patients with liver metastasis of neuroendocrine tumors of different pathologic grades and different primary sites.</p><p><strong>Methods: </strong>A retrospective analysis was performed on patients with liver metastases of neuroendocrine tumors in this study. The patients were divided into simultaneous ablation group and TACE group according to treatment mode and subgroups. The endpoints of prognosis were progression-free survival (PFS) and overall survival (OS).</p><p><strong>Results: </strong>A total of 108 patients with neuroendocrine tumors were collected, including 46 patients in the simultaneous ablation group and 62 patients in the TACE group. According to WHO classification, 21 patients with G1 grade, 55 patients with G2 grade and 32 patients with G3 grade were included. The median OS and the median PFS showed no statistically significant differences between the TACE group and the simultaneous ablation group. Among G2 stage, the TACE group and the synchronous ablation group showed no difference in the median OS but statistically difference in the median PFS. For G1&2 stage patients, synchronous ablation showed longer median PFS than TACE. In pNET patients, although median OS showed no significant difference between the two groups, the synchronous ablation group achieved longer median PFS compared to the TACE group. Both the TACE group and the synchronous ablation group showed improved median OS in G1&2 stage patients relative to G3 stage patients.</p><p><strong>Conclusions: </strong>Simultaneous ablation can delay disease progression in patients with liver metastasis of neuroendocrine tumors to a certain extent, and has a good safety, especially for patients with liver metastases of neuroendocrine tumors of intermediate or low grade or pancreatic origin.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 8","pages":"227"},"PeriodicalIF":2.8,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12331546/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144799171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early versus delayed postoperative extubation after elective neurosurgical treatment of brain metastasis.","authors":"Logman Khalafov, T Lampmann, M Hamed, J Dittmer, I Maiseyeu, H Alenezi, M Jaber, H Asoglu, M Thudium, F Lehmann, S Ehrentraut, J Poth, H Vatter, M Schneider, M Banat","doi":"10.1007/s00432-025-06278-8","DOIUrl":"10.1007/s00432-025-06278-8","url":null,"abstract":"<p><strong>Introduction: </strong>It is generally assumed that early extubation after elective neurosurgical treatment of brain metastases (BMs) is associated with a lower rate of adverse events (AE), such as an increased rate of respiratory infections. The aim of this study is to investigate to what extent this association holds for the patient cohorts of our clinic who underwent elective intracranial surgery and whether in our experience early extubation (EE) was inferior to delayed extubation (DE).</p><p><strong>Material and methods: </strong>Between 2018 and 2020, 190 patients were surgically treated for BM in the authors' neurosurgery department. Early extubation was defined as extubation immediately after surgery in the recovery room. The DE group was electively extubated after surgery in the intensive care unit. We analyzed demographic data, ASA status, blood loss, comorbidities, duration of surgery, blood transfusion, length of hospital stay, surgical-related complications and adverse events.</p><p><strong>Results: </strong>A total of 65 patients (34.2%) were extubated early. In the remaining 65.8% of patients extubation was delayed. In the univariate analysis, no statistical significance was found between the two groups, particularly with regard to complications. The only relevant difference was in the DE group, who had greater transfusion requirements (p = 0.037). The DE group showed more AE, but this was not significant in the multivariate analysis.</p><p><strong>Conclusions: </strong>Our data demonstrate that early extubation was justifiable and safe for our patients. Early extubation in the recovery room did not pose a risk of re-intubation immediately after elective neurosurgical resection of a brain metastasis.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 8","pages":"226"},"PeriodicalIF":2.8,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12321737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, regional, and national burden of ovarian cancer in women aged 45 + from 1990 to 2021 and projections for 2050: a systematic analysis based on the 2021 global burden of disease study.","authors":"Yanan Ren, Ren Xu, Yazhuo Wang, LuYang Su, Jianzhi Su","doi":"10.1007/s00432-025-06277-9","DOIUrl":"10.1007/s00432-025-06277-9","url":null,"abstract":"<p><strong>Purpose: </strong>Ovarian cancer is the most common cause of gynecologic cancer-related deaths. We aimed to assess the global, regional, and national burdens and trends of Ovarian Cancer in Women Aged 45 + from 1990 to 2019 and Projections for 2050, utilizing data from the most recent Global Burden of Disease (GBD) 2021 database.</p><p><strong>Methods: </strong>Age-standardized rates of incidence, prevalence, mortality, and disability-adjusted life years (DALYs) were analyzed using GBD 2021 data. Temporal trends were assessed using estimated annual percentage change (EAPC). Regional disparities were examined via the Socio-Demographic Index (SDI). Age-Period-Cohort (APC) models assessed disease dynamics, while Bayesian APC (BAPC) modeling projected trends to 2050.</p><p><strong>Results: </strong>In 2021, global ovarian cancer incidence, prevalence, mortality, and DALYs in women aged 45 + were 239,682; 843,405; 171,246; and 4,352,539, respectively. The global burden declined significantly from 1990 to 2021 and is projected to remain stable through 2050. However, regional disparities persist: High and High-middle SDI regions saw decreases, while Middle to Low SDI regions experienced increases. Burden increased with SDI up to 0.8, then declined. Population growth was the primary contributor, followed by epidemiologic transitions and aging. The 55-59 age group showed the highest morbidity and DALYs; mortality peaked at 65-69 years.</p><p><strong>Conclusions: </strong>Although the overall burden of ovarian cancer in women aged 45 + is declining globally, marked regional disparities underscore the need for tailored prevention and treatment strategies to further reduce disease impact and improve outcomes.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 8","pages":"225"},"PeriodicalIF":2.8,"publicationDate":"2025-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12317933/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144768676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study.","authors":"Irene Mangues-Bafalluy, Beatriz Bernardez, José Manuel Martínez-Sesmero, Andres Navarro-Ruiz, Maria Teresa Martín-Conde, Ana Rosa Rubio-Salvador, Judith Rius-Perera, Marta Gilabert-Sotoca, Marta Domínguez López, Angel Callejo Mellén","doi":"10.1007/s00432-025-06264-0","DOIUrl":"10.1007/s00432-025-06264-0","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 8","pages":"224"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12316616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144760185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High PER1 expression is associated with STK11 mutation and clinical biomarkers of immunotherapy resistance in lung adenocarcinoma.","authors":"Rebecca E Parker, Leon McSwain, Wei Zhou, Adam I Marcus, Haian Fu, Suresh S Ramalingam, Shirley Zhang, Melissa Gilbert-Ross","doi":"10.1007/s00432-025-06269-9","DOIUrl":"10.1007/s00432-025-06269-9","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 7","pages":"223"},"PeriodicalIF":2.8,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12297223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144717875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The risk of mortality from multiple primary cancers in colorectal cancer survivors: analysis of data from the South Australian Cancer Registry.","authors":"Mulugeta Melku, Oliver G Best, Jean M Winter, Lauren A Thurgood, Ganessan Kichenadasse, Molla M Wassie, Muktar Ahmed, Erin L Symonds","doi":"10.1007/s00432-025-06268-w","DOIUrl":"10.1007/s00432-025-06268-w","url":null,"abstract":"<p><strong>Purpose: </strong>Colorectal cancer (CRC) survivors face an increased risk of multiple primary cancers (MPCs), but evidence on MPC-related mortality is limited.</p><p><strong>Methods: </strong>Using data from the South Australian Cancer Registry (1982-2017), this retrospective study analysed CRC survivors diagnosed with MPCs, defined as distinct primary cancers arising ≥ 2 months after CRC diagnosis. Causes of death were categorised as index CRC, MPC, or non-cancer related. Poisson regression estimated cancer-specific mortality risk compared to the general population. Propensity score weighting was applied to balance covariate distribution between CRC survivors with and without MPC groups. A hazard ratio (HR) for all-cause mortality was estimated using a weighted dataset to assess the impact of MPC on overall survival.</p><p><strong>Results: </strong>Among 26,093 CRC survivors (181,877 person-years follow-up), the age-standardised MPC-related mortality rate was 240 per 100,000 population. Gastrointestinal, lung, haematological, and urinary tract cancers were the most common MPC-related causes of death. CRC survivors had a 45% higher risk of dying from MPCs than the general population (standardised mortality ratio = 1.45, 95%CI 1.38-1.52). Adjusted analyses showed a 58% increase in all-cause mortality among CRC survivors with MPCs (HR = 1.58, 95%CI 1.51-1.65).</p><p><strong>Conclusions: </strong>CRC survivors with MPC face significantly worse survival compared to those with a single primary CRC. Early detection and management of MPCs are essential for improving long-term survival in individuals diagnosed with CRC.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 7","pages":"222"},"PeriodicalIF":2.8,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12297194/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decoding epithelial-fibroblast interactions in lung adenocarcinoma through single-cell and spatial transcriptomics.","authors":"Jiajin Yang, Qiuping Xu, Yanjun Lu","doi":"10.1007/s00432-025-06250-6","DOIUrl":"10.1007/s00432-025-06250-6","url":null,"abstract":"<p><strong>Background: </strong>Lung adenocarcinoma (LUAD) exhibits significant cellular heterogeneity, yet the precise interactions between epithelial and stromal cells remain unclear. This study integrates single-cell and spatial transcriptomics to delineate tumor microenvironment dynamics, aiming to uncover key cellular subpopulations and their roles in LUAD progression.</p><p><strong>Methods: </strong>We analyzed single-cell RNA sequencing (scRNA-seq) data from 21 LUAD patients and performed spatial transcriptomic deconvolution. Epithelial and fibroblast subpopulations were identified using Seurat and Harmony. Cell-cell communication was inferred via CellChat, while metabolic interactions were assessed using MEBOCOST. Copy number variation (CNV) analysis distinguished malignant cells, and trajectory inference mapped differentiation states. Spatial colocalization was examined via CellTrek. Prognostic signatures were derived from Cox regression, and a six-gene MCI score was validated using survival analysis.</p><p><strong>Results: </strong>We identified eight epithelial (e.g., MUC21 + Epi, ASCL1 + Epi) and nine fibroblast subpopulations (e.g., Fb_IGFBP4, Fb_COL11A1), with tumor-enriched subsets showing elevated CNVs and metabolic crosstalk. Fb_IGFBP4 correlated with poor prognosis, while MUC21 + Epi exhibited amplified COL1A1/SDC4-mediated interactions with fibroblasts. Pathway analysis highlighted tumor-specific MK and collagen signaling between fibroblasts and epithelial cells, suggesting stromal-epithelial synergy drives progression. Spatial analysis revealed colocalization of epithelial and fibroblast subclusters in tumors, contrasting with normal tissue. The MCI score, derived from six genes (e.g., ADAM10, MARVELD1), independently predicted survival and stratified high-risk patients (AUC > 0.6).</p><p><strong>Conclusion: </strong>This study identifies key stromal-epithelial subset interactions in LUAD, proposing prognostic biomarkers and therapeutic targets.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 7","pages":"221"},"PeriodicalIF":2.8,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12290149/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and treatment evaluation of diffuse large B-cell lymphoma in Chinese children and adolescents: a multicenter clinical study of China-Net childhood lymphoma group B-NHL-2017.","authors":"Yang Fu, Ling Jin, Yanlong Duan, Jing Yang, Ying Liu, Bo Hu, Mincui Zheng, Yunpeng Dai, Ansheng Liu, Wei Liu, Leping Zhang, Fu Li, Baoxi Zhang, Xiaojun Yuan, Lirong Sun, Rong Liu, Zhuoyu Wen, Runming Jin, Shuquan Zhuang, Lian Jiang, Yufeng Liu, Haixia Zhou, Chen Shen, Hongsheng Wang, Yonghong Zhang, Xiaowen Zhai","doi":"10.1007/s00432-025-06260-4","DOIUrl":"10.1007/s00432-025-06260-4","url":null,"abstract":"<p><strong>Background: </strong>China-Net Childhood Lymphoma (CNCL) group B-NHL-2017 study is a prospective multi-center study in China, with the purpose of standardizing the diagnosis and treatment of childhood lymphoma, and improving the prognosis.</p><p><strong>Methods: </strong>From May 2017 to June 2023, 20 centers participated in the diffuse large B-cell lymphoma (DLBCL) study. The clinical data were analyzed to summarize the clinical characteristics, treatment response and outcome. The primary endpoint was 5-year event-free survival (EFS). The trial is registered with the Chinese Clinical Trial Registry (ChiCTR1800020067).</p><p><strong>Results: </strong>A total of 138 children and adolescents were enrolled, including 101 males and 37 females. The median age of disease diagnosis was 9.0 years (range: 2.3-15.5 years). The range of follow-up time was 17 d-6.0 years. A total of 12 events occurred in this study, including 7 deaths. of which 4 patients died of disease and chemotherapy comorbidities (severe infection, septic shock, etc.), 1 died of disease progression (enlargement of the primary tumor and tumor metastasis), 1 died of recurrence, and 1 died of severe pneumonia in the third year after completing all chemotherapy courses. Recurrence occurred in 6 (4.3%) patients at 14.9 months (range: 4.4-32.6 months) after initial treatment. The 5-year overall survival (OS) was 90.7 ± 5.0% and the 5-year EFS was 85.5 ± 5.4%. Based on Cox regression analysis, no Rituximab during treatment is an independent risk factor for mortality in patients with DLBCL.</p><p><strong>Conclusion: </strong>The efficacy of CNCL-B-NHL-2017 protocol in the treatment of DLBCL in children and adolescents is close to results of international studies.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 7","pages":"220"},"PeriodicalIF":2.8,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between MRI radiomics analysis and tumor-micro milieu in uterine cervical cancer.","authors":"Hans-Jonas Meyer, Jakob Leonhardi, Anne-Kathrin Höhn, Noura Kabbani, Silke Zimmermann, Jan Borggrefe, Alexey Surov","doi":"10.1007/s00432-025-06253-3","DOIUrl":"10.1007/s00432-025-06253-3","url":null,"abstract":"<p><strong>Purpose: </strong>The complex interactions of the tumor micromilieu could be reflected by magnetic resonance imaging (MRI) when analyzed with the radiomics approach. For several tumor entities, it has been shown that radiomics derived from MRI can reflect important characteristics of the tumors. The present study investigated the association radiomics derived from MRI images and histopathological features in uterine cervical cancer.</p><p><strong>Methods: </strong>The MRI before any treatment was used to extract the radiomics features of T1- and T2-weighted images. The biopsy specimens were stained for Ki 67, e-cadherin, vimentin, programmed-death ligand 1, and tumor-infiltrating lymphocytes (TIL, all CD45 positive cells). Tumor-stroma ratio (TSR) was calculated on routine H&E specimen. Spearman's correlation analysis and discrimination analyses were performed as statistical analyses.</p><p><strong>Results: </strong>The patient sample was comprised of 89 female patients with a mean age of 49.3 years ± 14.6 (range 27-77 years) with squamous cell cervical carcinoma. \"Kurtosis\" derived from T1-weighted images after contrast media application correlated with the Ki-67 index (r = 0.28, p = 0.02). \"WavEnHL_s-4\" derived from T2-weighted images and \"S(1.0)Contrast\" derived from T1-weighted images after contrast media application showed correlations with TSR (r = - 0.24, p = 0.04, each). Several associations were identified between the radiomics features with immune scores defined by programmed-death ligand 1, the highest correlation showed Teta1 derived from T2-weighted images with the combined positive score (r = - 0.38, p < 0.01). There were several associations with vimentin expression, the highest showed \"Variance\" derived from T1-weighted images after contrast media application (r = 0.46, p < 0.01).</p><p><strong>Conclusions: </strong>Radiomics features derived from MRI can reflect tumor characteristics of UCC. Especially immune-related features were reflected by the MRI texture features. Proliferation potential, composition of the extracellular matrix and tumor-stroma ratio were also significantly associated with radiomics features. These presented results need to be evaluated in an independent cohort to test their stability.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 7","pages":"219"},"PeriodicalIF":2.8,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12279667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}